Status:
COMPLETED
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborating Sponsors:
Paragon Biomedical
Conditions:
Moderate to Severe Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Eligibility Criteria
Inclusion
- Diagnosis of Psoriasis for 6 MO
- BSA 10%
- PASI 12 or above
- PGA 3 or above
Exclusion
- Previous exposure to either etanercept or ABT-874
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00710580
Start Date
July 1 2008
End Date
April 1 2009
Last Update
January 18 2013
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 9984
Birmingham, Alabama, United States, 35205
2
Site Reference ID/Investigator# 10605
Birmingham, Alabama, United States, 35233
3
Site Reference ID/Investigator# 10001
Scottsdale, Arizona, United States, 85251
4
Site Reference ID/Investigator# 10502
Little Rock, Arkansas, United States, 72205